Ocular Therapeutix Inc. - notizie pubblicate 213 - letture 2.938
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
Industry leader and retina expert, pravin u. dugel, md, becomes executive chair jeffrey s. heier, md to become chief scientific officer, peter k. kaiser, md to be medical director, ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement - Form 8-K
Ocular therapeutix, inc. announces $325.0 million private placement bedford, ma, february 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) (the "company&quo ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
Bedford, mass., feb. 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) ("ocular"), a biopharmaceutical company committed to enhancing people's vision an ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
Bedford, mass., feb. 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) (the "company"), a biopharmaceutical company committed to enhancing people's visi ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
Industry leader and retina expert, pravin u. dugel, md, becomes executive chair jeffrey s. heier, md to become chief scientific officer, peter k. kaiser, md to be medical director, ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement - Form 8-K
Ocular therapeutix, inc. announces $325.0 million private placement bedford, ma, february 22, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul) (the "company&quo ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
Strategic promotion underscores commitment to commercial growth across ocular portfolio bedford, mass., feb. 15, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul), a ...
OCULAR THERAPEUTIX INC.
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Phase 3 sol-1 study will evaluate the efficacy and safety of axpaxli in wet amd bedford, mass., feb. 13, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq:ocul), a biopharm ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
OCULAR THERAPEUTIX INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti